Southern Oncology Clinical Research Unit
Southern Oncology Clinical Research Unit
Bedford Park, South Australia, Australia7 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer | DNA Virus Infections, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Head and Neck Neoplasms, Infections, Male Urogenital Diseases, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Tumor Virus Infections, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, cutaneous melanoma, cutaneous neuroendocrine carcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, gastric neoplasm, head and neck squamous cell carcinoma, kidney cancer, kidney disorder, lung disorder, lung neoplasm, melanocytic neoplasm, melanoma, metastatic malignant neoplasm, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, non-small cell lung carcinoma, polyomavirus infectious disease, primitive neuroectodermal tumor, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, skin neoplasm, squamous cell carcinoma, stomach disorder, type 1 diabetes mellitus 10, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, viral infectious disease | Recruiting | Phase 1 / Phase 2 | 2026-09-18 | NCT05267626 | |
| Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Male Urogenital Diseases, Mouth Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Stomatognathic Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, adenocarcinoma, adenoid cystic carcinoma, benign urinary system neoplasm, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, cervix disorder, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, esophageal cancer, esophageal disorder, female reproductive system disorder, female reproductive system neoplasm, gastric cancer, gastric neoplasm, gastroesophageal junction adenocarcinoma, gonadal disorder, intestinal disorder, kidney cancer, kidney disorder, lung disorder, lung neoplasm, male reproductive organ cancer, male reproductive system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, melanocytic neoplasm, melanoma, metastatic melanoma, metastatic prostate carcinoma, mouth disorder, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, pancreas disorder, pancreatic neoplasm, primitive neuroectodermal tumor, prostate cancer, prostate disorder, rectal disorder, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, salivary gland cancer, salivary gland disorder, sarcoma, skin disorder, skin neoplasm, small cell lung carcinoma, stomach disorder, transitional cell carcinoma, urinary system disorder, urothelial carcinoma, uterine disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-14 | NCT04140526 | |
| ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Recruiting | Phase 1 | 2026-09-09 | NCT06597721 | |
| First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors | Solid Tumors (Phase 1) | Recruiting | Phase 1 | 2026-07-24 | NCT07362888 | |
| A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors. | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DNA repair disease, Genomic Instability, Microsatellite Instability, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Werner syndrome, hereditary disease, metabolic disease | Recruiting | Phase 1 / Phase 2 | 2026-05-06 | NCT06898450 | |
| Trial of INI-4001 in Patients With Advanced Solid Tumours | Advanced Solid Tumor | Recruiting | Phase 1 | 2026-01-16 | NCT06302426 | |
| A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors | Locally Advanced or Metastatic Solid Tumors | Recruiting | Phase 1 | 2025-06-09 | NCT05205109 |